

# Genomics and drug profiling of fatal *TCF3-HLF*-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

*TCF3-HLF*-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in *TCF3-HLF*-positive and treatment-responsive *TCF3-PBX1*-positive ALL. We identified recurrent intragenic deletions of *PAX5* or *VPREB1* in constellation with the fusion of *TCF3* and *HLF*. Moreover somatic mutations in the non-translocated allele of *TCF3* and a reduction of *PAX5* gene dosage in *TCF3-HLF* ALL suggest cooperation within a restricted genetic context. The enrichment for stem cell and myeloid features in the *TCF3-HLF* signature may reflect reprogramming by *TCF3-HLF* of a lymphoid-committed cell of origin toward a hybrid, drug-resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for *TCF3-HLF* ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development. Striking on-target sensitivity was achieved with the *BCL2*-specific inhibitor venetoclax (ABT-199). This integrated approach thus provides alternative treatment options for this deadly disease.

One of the hallmarks of pediatric ALL is the presence of subtype-defining chromosomal translocations that cause gene fusions involving master regulators of hematopoietic development. These initiating lesions often cooperate with specific somatic aberrations, including monoallelic deletions of B cell developmental genes, such as *PAX5*, *IKZF1* and *EBF1* (ref. 1). Other cooperative liaisons are represented by trisomy 21q22 with *CRLF2* activation<sup>2–4</sup> or near-haploid ALL with activation of receptor tyrosine kinase or RAS signaling<sup>5</sup>. RAS pathway mutations appear in high-risk ALL but are often lost with disease progression, which suggests involvement of additional tumorigenic factors<sup>6,7</sup>. The patterns of recurrent genomic alterations need to be better understood, because apart from tyrosine kinase inhibitor-supplemented treatment of *BCR-ABL1*-positive ALL, the only proven successful first-line treatment strategies for high-risk ALL are chemotherapy intensification and early allogeneic hematopoietic stem cell transplantation<sup>8</sup>.

The translocation t(1;19)<sup>9</sup> that results in a fusion of the transcriptional activation domain of the B cell developmental transcription factor *TCF3* to the DNA-binding domain of *PBX1* occurs in about 5–10% of precursor B cell (pre-B cell) ALL patients and is associated with a median five-year event-free survival probability of 78–85%<sup>10</sup>. In contrast, the translocation t(17;19)(q22;p13), resulting in the fusion gene *TCF3-HLF*, defines a rare subtype of ALL (<1% of pediatric ALL) that is typically associated with relapse and death within two years from diagnosis<sup>11,12</sup>. Both translocations disrupt one allele of *TCF3*, which drives the B cell differentiation program upstream of the transcription factor *PAX5* (ref. 13). As an initiating event, expression of *TCF3-HLF* leads to transcriptional reprogramming in pre-leukemic cells. Possible direct targets of *TCF3-HLF* include the transcription factor gene *LMO2*, which is implicated in initiation of T cell ALL<sup>14,15</sup>, and

the transcriptional repressor *SNAIL* (*SLUG*), which regulates embryonic development and apoptosis<sup>16,17</sup>. Further targets have been proposed, including *BCL2* (ref. 14). The *TCF3-HLF* fusion likely requires additional events to cause leukemia, because *TCF3-HLF* transgenic and knock-in mice did not recapitulate the human phenotype<sup>18,19</sup>.

Here we report that the genomic and transcriptomic landscape of *TCF3-HLF*-positive ALL differs markedly from *TCF3-PBX1*-positive ALL. The *TCF3-HLF* fusion likely occurs in B lymphoid progenitors in the context of *PAX5* haploinsufficiency and is associated with transcriptional reprogramming toward an immature, hybrid hematopoietic state. Drug response profiling in patient-derived xenografts, which maintained the genomic and global transcriptome landscapes of the corresponding primary leukemic samples, identified resistance patterns to drugs commonly used for the treatment of *TCF3-HLF*-positive patients. A general trait of *TCF3-HLF*-positive ALL in our study is extreme sensitivity toward the *BCL2*-specific inhibitor ABT-199 (venetoclax), indicating new therapeutic options for this fatal ALL subtype.

## RESULTS

### The *TCF3-HLF* ALL patient cohort


We applied high-throughput sequencing analysis integrating short and large insert size paired-end whole-genome, whole-exome and transcriptome sequencing to a discovery cohort consisting of five diagnostic pre-treatment samples of *TCF3-PBX1*-positive ALL (samples 1a–5a) and *TCF3-HLF*-positive ALL (samples 6a–9a and 11a). As nontumor controls we used matched bone marrow samples collected after induction treatment for minimal residual disease (MRD) evaluation (maximum leukemic cell load  $\leq 10^{-3}$ ; samples

A full list of authors and affiliations appears at the end of the paper.

Received 2 December 2014; accepted 29 June 2015; published online 27 July 2015; doi:10.1038/ng.3362

**Figure 1** Genetic lesions identified in pediatric *TCF3-HLF*- and *TCF3-PBX1*-positive ALL.

(a) Breakpoints in *TCF3*, *PBX1* and *HLF* cluster in genomic hotspot regions. Boxes correspond to exonic regions; arcs represent fusions in patient samples. (b) *TCF3* breakpoints cluster in two *TCF3* intronic regions: between exons 16 and 17 (type I) and between exons 15 and 16 (type II). On the transcript level, type I translocations join *TCF3* exon 16 to *HLF* exon 4, including inserted nontemplate and intronic sequences and new splice acceptor sites (patients 8 and 9). Type II translocations occur downstream of exon 15 and exclude *TCF3* exon 16 from the fusion transcript (patients 6, 7 and 11). (c) Schematic of somatic structural and nucleotide variations in samples. *TCF3-HLF*-positive ALL is characterized by mutually exclusive *PAX5*, *BTG1* and *VPREB1* deletions and nonsynonymous nucleotide variations in *TCF3* (p.Asp561Val, 'D561V' in patient 8). Indel, insertion-deletion. Recurrently affected genes are indicated by bold symbols. (d) Models of wild-type and mutant *TCF3* based on the crystal structure of *TCF3* in complex with the transcription factors *SCL*, *LMO2* and *LDB1* bound to DNA<sup>58</sup>. Upon *LMO2* binding, bonds are formed between *TCF3* and *SCL*, including a hydrogen bond (dashed line) between D561 and R230, reducing the DNA binding capacity of the complex. Inset, D561V introduces a hydrophobic valine residue close to polar residues that may interfere with hydrogen bonding, thus altering the DNA-binding properties of the complex.



1b–9b and 11b; **Supplementary Table 1**).


For validation, we used additional DNA samples from seven *TCF3-HLF*-positive cases (diagnostic samples 10a, 12a, 13a, 14a, 15a, 16a, 17a, remission samples 10b, 12b, 13b) and 24 *TCF3-PBX1*-positive cases (**Supplementary Tables 2 and 3**). In most cases *TCF3-HLF*-positive ALL responded to induction chemotherapy but remained MRD-positive. Nine children included in this study died owing to disease progression and treatment-related toxicities within 2 years on average, and only one patient is in remission after a short follow-up time, reflecting the dismal prognosis of *TCF3-HLF*-positive ALL.

### *TCF3* breakpoints suggest a committed lymphoid cell of origin

Consistent with previous reports<sup>20,21</sup>, all *TCF3* translocation breakpoints were restricted to three hotspot regions (**Fig. 1a,b** and **Supplementary Fig. 1**). Those were associated with small nontemplate nucleotide insertions indicative of terminal deoxynucleotidyl transferase (TdT) activity characteristic of an early B cell stage (**Supplementary Table 4**). In *TCF3*, the breakpoints clustered in close proximity to CpG elements in the absence of classical RAG consensus sequence sites (**Supplementary Fig. 1**), which is a characteristic feature of translocations that occur in lymphoid progenitors at the pro-/pre-B stage. This may represent illegitimate RAG-mediated recombination at cryptic sites, possibly in the context of deaminated CpG nucleotides as proposed for *TCF3-PBX1* translocations<sup>22</sup>. Consistent with the idea that *TCF3-HLF* fusion may occur at a lymphoid-committed rather than a pluripotent progenitor stage, we detected this translocation only in sorted pre-B cell populations containing leukemic cells but neither in stem cells nor in myeloid progenitor cells (**Supplementary Fig. 2**).

### *TCF3-HLF* ALL and impaired pro- to pre-B cell transition

Pre-B cell ALL is frequently associated with somatic copy number alterations affecting B cell developmental genes. *PAX5* deletions are generally observed in 13% of ALL cases and in up to 28% of high-risk ALL<sup>23</sup>. We observed enrichment for monoallelic *PAX5* deletions in *TCF3-HLF*-positive ALL, identifying such events in 67% of the cases (**Fig. 1c** and **Supplementary Table 2**). Illegitimate RAG-mediated recombination appears to be implicated in the generation of such events in *TCF3-HLF*-positive ALL, given the close proximity to RSS motifs (**Supplementary Table 5**). In most samples without *PAX5* deletion, we identified hemi- and homozygous deletions of *VPREB1*, which encodes a component of the surrogate light chain of the pre-B cell receptor (**Fig. 1c** and **Supplementary Table 6**), independent of the lambda light chain locus. *VPREB1* deletions in pediatric ALL result in failure to form a viable surrogate light chain in the pre-B cell receptor, an event associated with lower overall survival<sup>24</sup>. In addition, we detected *BTG1* gene deletions in three of eight *TCF3-HLF*-positive cases without *PAX5* deletions (**Supplementary Fig. 3a,b**). *BTG1* deletions occur frequently in ALL positive for *ETV6-RUNX1* (19%) or *BCR-ABL1* (26%) and may confer a proliferative advantage<sup>25</sup>. In contrast, we detected no deletion, but only a single *PAX5* nonsense mutation in 29 *TCF3-PBX1*-positive cases (**Fig. 1** and **Supplementary Table 3**). Our results indicate that cooperative genetic events affecting genes regulating the pro- to pre-B cell transition, in particular *PAX5*, *BTG1* and *VPREB1*, but not *IKZF1*, are selected in *TCF3-HLF*-translocated cells. Other deleted genes associated with pre-B cell ALL<sup>26</sup> were *JAK2* and *CDKN2A/B* (patient 7a and 11a) and transcriptional regulators such as *ERG*, *NCOR1*, *TOX*, *BACH2*, *BCL7C*, *MLL3*, *SMARCA2* and *MAFK* (**Fig. 1c**).



**Figure 2** *TCF3-HLF* programs leukemia to a hybrid hematopoietic transcriptional state. **(a)** Heatmap of the 401 differentially expressed genes between the two ALL subtypes (edgeR,  $\log_2(\text{fold change}) \geq 1$ , false discovery rate (FDR)  $\leq 0.001$ ). **(b)** Enriched hematopoietic stages in *TCF3-HLF*-positive (orange) and *TCF3-PBX1*-positive (green) ALL. Stages shown include hematopoietic stem cells (HSC), common myeloid progenitors (CMP), lymphoid-specified progenitors (GMP and MEP), neutrophils (NEUTRO), monocytes (MONO), multilymphoid progenitor (MLP), early T cell precursors (ETP), pro-B cells (PROB), T cells (TCELL) and B cells (BCELL). Gene set enrichment analysis was carried out using a Genomatix genome analyzer and gene set enrichment analysis (GSEA)<sup>77</sup> (GSEA: FDR  $\leq 0.02$ ; Genomatix genome analyzer: adjusted  $P \leq 0.02$ ). The source of the significantly enriched gene sets is noted by the superscript: 1, curated gene sets of hematopoietic precursors<sup>31</sup>; 2, human immunologic gene signatures (MSigDB v4.0)<sup>32</sup>; 3, text mining-based tissue-specific gene sets<sup>78</sup>. **(c)** Enrichment plot for the HSC signature<sup>31</sup>. FDR, false discovery rate. NES, normalized enrichment score. **(d)** Components of the *TCF3-HLF*-positive ALL signature reveal functional annotation related to stem cells and their cellular location (Genomatix genome analyzer:  $P = 4.65 \times 10^{-4}$ , adjusted  $P < 0.001$ ).

### Recurrent RAS pathway mutations in *TCF3-HLF* ALL

We identified only a few additional somatic alterations affecting protein-coding sequences in both *TCF3-PBX1*- and *TCF3-HLF*-positive ALL (Fig. 1c, and Supplementary Tables 6 and 7), involving among others, genes associated with pre-B cell ALL<sup>26</sup> (*TCF3*, *PAX5* and *LEF1*) and transcriptional and chromatin regulation (*ZNF263*, *MLL2*, *HIST1H3A* and *C6orf89*). We observed a prominent association of *TCF3-HLF*-positive ALL with activating mutations in RAS signaling pathway genes (*NRAS*, *KRAS* and *PTPN11*), detectable in four of five discovery cases (Fig. 1c) and in three of five additional *TCF3-HLF*-positive validation samples (*PTPN11* and *SPHK1*) (Supplementary Table 2). We identified no RAS pathway mutations in the *TCF3-PBX1*-positive discovery cohort and only one oncogenic *NRAS* mutation in the 24 *TCF3-PBX1*-positive validation cases (Supplementary Table 3). *NRAS* and *KRAS* mutations were generally detected in subclones (Supplementary Table 7). We discovered a new fusion gene, *KHDRBS1-LCK*, due to an interstitial chromosomal deletion in one *TCF3-HLF*-positive sample (6a), triggering the overexpression of the *LCK* tyrosine kinase (Supplementary Fig. 4). This was also present in three of 74 randomly selected ALL samples, demonstrating that *KHDRBS1-LCK* fusion is recurrent in ALL (Supplementary Fig. 5). *LCK* is a drug target in RAS-dependent cancer cells that have higher *LCK* expression<sup>27</sup>, suggesting a possible interplay with RAS-related signaling networks in *TCF3-HLF*-positive ALL. Oncogenic activation of *LCK* associated with t(1;7)(p34;q34) translocation had been reported in the T cell leukemia cell line HSB2 (ref. 28). Our data indicate a frequent association of proliferation-driving mutations in *TCF3-HLF*-positive ALL in the context of stalled B cell differentiation.

### Mutations affecting the second *TCF3* allele in *TCF3-HLF* ALL

We identified a mutation in the basic helix-loop-helix region of *TCF3* (p.Asp561Val, D561V, Fig. 1c,d) affecting the non-translocated

chromosome in one *TCF3-HLF*-positive case (8a). Mutations at this position have been reported in sporadic Burkitt lymphoma<sup>29</sup> and may reduce binding to its negative regulator ID3 (ref. 29). Based on available crystal structure data, p.Asp561Glu may affect the interaction of *TCF3* with the transcription factor SCL (also known as TAL1; Fig. 1d), possibly altering *TCF3* protein complexes. We detected a second *TCF3* mutation (p.Ser467Gly) in another *TCF3-HLF*-positive case (13a, Supplementary Table 2). The functional consequences of this mutation are currently unclear. We could not detect any somatic mutations in *TCF3* by targeted sequencing of 1,033 unselected ALL patients from the European multicenter trial AIEOP-BFM ALL 2000, suggesting a specific association with *TCF3-HLF*-positive ALL (Supplementary Table 8). Thus, deregulation of normal *TCF3* function may also contribute to *TCF3-HLF*-positive ALL. Corroborating our findings, a recent study included a single *TCF3-HLF* case, as part of a cohort comparing diagnostic and relapse ALL samples, which showed a *PAX5* deletion and two mutations in *TCF3* (p.His460Tyr and p.Gly470fs), all of which were conserved at relapse<sup>30</sup>. The relapse sample featured a *VPREB1* deletion as well as a shift in subclonal mutations in *NRAS* (p.Gly12Asp and p.Gly12Val), reinforcing the idea of cooperative effects between *TCF3-HLF*, and alteration of *PAX5* and *VPREB1* gene dosage. Taken together, seven of 11 *TCF3-HLF* cases were hemizygous for *PAX5*, whereas five samples featured *VPREB1* deletions (Supplementary Fig. 6).

### Reprogramming toward a more immature state in *TCF3-HLF* ALL


Consistent with the occurrence of *TCF3-HLF* and *TCF3-PBX1* translocations in lymphoid precursors, both leukemia subtypes had in common a gene expression signature of B lymphoid cells (including *PAX5*, *BLK*, *CD19*, *CD22*, *CD79B*, *TCF3*, *EBF1*, *VPREB1*, *RAG1*, *ROR1*, *BLNK* and *DNTT*; Supplementary Tables 9 and 10), but differential expression of 401 genes (false discovery rate  $\leq 0.001$ ) strongly distinguished

**Figure 3** The genomic landscape of *TCF3-HLF*- and *TCF3-PBX1*-positive ALL is preserved in patient-derived leukemia xenografts.

(a) Xenografts were established from cryopreserved patient samples at diagnosis (samples "a"), at follow-up with minimal residual disease (MRD, <1 leukemic cell in 10,000 cells, samples "b") or from disease progression (samples "c") and subjected to whole exome and transcriptome sequencing as well as multiplex ligation-dependent probe amplification (MLPA). All available MRD samples from *TCF3-HLF*-positive cases were successfully engrafted. (b) Comparison of all transcriptionally expressed nucleotide variations and of selected recurrent deletions frequently found in pediatric ALL in corresponding patient (P) and xenograft (X) samples. Deletions and nucleotide variations are colored according to their frequency in the analyzed leukemic cell population. Deletion frequencies were calculated by integrating whole genome and whole exome sequencing data with MLPA data. Nucleotide variation frequencies were calculated by integrating whole genome, whole exome and transcriptome sequencing data. Recurrently affected genes are indicated by bold symbols.

the two *TCF3*-translocated subtypes (Fig. 2a, and Supplementary Tables 11 and 12). *In silico* prediction of transcription factor binding sites in the corresponding promoter regions revealed enrichment for PBX ( $Z$  score = 3.72) and HLF ( $Z$  score = 2.99) binding motifs associated with *TCF3-PBX1* and *TCF3-HLF* gene signatures, respectively (Supplementary Tables 13 and 14). Further, *PBX1* and *HLF* were the only transcription factors among those with enriched binding motifs that were significantly differentially expressed between the two ALL subtypes, and between leukemia and remission samples. The chimeric *HLF* transcript was strongly induced in *TCF3-HLF*, but we detected no wild-type *HLF* expression. We predicted 39 potential HLF targets, including the known target *SNAI2* (*SLUG*)<sup>16</sup>, *GPC4* and *BMP3* involved in stem cell proliferation, which showed induced expression in *TCF3-HLF* samples (Supplementary Table 15). Other potential *TCF3-HLF* targets that regulate developmental programs and cell survival, such as *LMO2* (ref. 14) and *BCL2* (ref. 14), were not predicted. However, their expression was increased in *TCF3-HLF*-positive ALL.

Gene set enrichment analysis using gene sets from sorted human hematopoietic stem cells and early progenitor populations<sup>31</sup> as well as curated oncogenic (C6) and human immunologic (C7) signatures from MsigDB<sup>32</sup> revealed an enrichment for stem cell and myeloid signatures in *TCF3-HLF*-positive ALL. In contrast, lymphoid features were more prominent in *TCF3-PBX1*-positive ALL (Fig. 2b and Supplementary Table 16). The hematopoietic stem cell signature<sup>31</sup> ranked among the top gene sets enriched in *TCF3-HLF*-positive ALL (Fig. 2c and Supplementary Table 17). We obtained similar results using an independent method based on text mining annotations (Fig. 2d, and Supplementary Tables 18 and 19). We also consistently detected high expression of the stem cell marker *LGR5* (ref. 33) in *TCF3-HLF*-positive ALL, suggesting a reactivation of immature features shared with other stem cell populations. Consistent with previous reports, the myeloid marker *CD33* was expressed in *TCF3-HLF*-positive blasts, which provides a target for antibody-directed



therapy<sup>12,34</sup>. Other differentially expressed genes, such as *BMP2* (ref. 35), could present additional therapeutic targets.

Our results are consistent with a model in which *TCF3-HLF* arises in lymphoid cells and promotes transcriptional reprogramming toward a hybrid hematopoietic state. We also detected features of mesenchyme-derived tissues in *TCF3-HLF*-positive ALL, which may indicate a profound cellular reprogramming toward a drug-resistant state.

#### Mutation profiles of *TCF3-HLF* ALL are conserved in xenografts

We generated leukemia xenografts in nonobese diabetic severe combined immunodeficiency (NOD/SCID)/IL2 $\gamma$ <sup>null</sup> (NSG) mice for all cases included in this study (Supplementary Table 20)<sup>36,37</sup>. We also established for the first time to our knowledge leukemia xenografts from follow-up samples with MRD, some with less than 0.1% ALL cells after induction chemotherapy (Fig. 3a, and Supplementary Tables 1 and 20). Leukemia and MRD engraftment was rapid with conserved and predictable kinetics for xenografts derived from the same patient (Supplementary Fig. 7), suggesting that no major adaptation to the mouse microenvironment was needed for proliferation. Most SNVs and intra-chromosomal deletions that had been present at diagnosis were conserved in the corresponding xenografts (Fig. 3b and Supplementary Table 7). Only deletions detected in the relapse sample 11c were not conserved in the corresponding xenografts, and a deletion in *BTG1* emerged in one MRD-derived sample (7b, Supplementary Fig. 3c,d). A few mutations were lost in MRD or relapse xenograft samples, including *GNB1* and *DDX3X*, indicating that these are probably dispensable or may cause drug sensitivity. Mutations in the RAS pathway were largely maintained in xenografts. However, the *NRAS* mutation p.Gln61His identified in the primary

MRD sample 7b was not detected in the corresponding xenograft. Instead, we identified a heterozygous damaging mutation in *KRAS* (p.Lys147Glu) associated with Noonan syndrome<sup>38</sup>. In patient 9a, we identified two subclones displaying either a *KRAS* (p.Gly13Asp) or an *NRAS* (p.Gly12Ser) mutation. The corresponding xenograft retained only the *KRAS* mutated subclone. Thus, maintenance and acquisition of RAS pathway mutations in xenografts support the notion that they occur later during selection at a multiclonal level and confer a selective advantage in *TCF3-HLF*-positive ALL. No other SNVs emerged *de novo* in the xenografts. In summary, the molecular characteristics of both leukemia subtypes were largely conserved in the xenografts, confirming the validity of this model.

### *TCF3-HLF*-associated gene expression is maintained in xenografts

Hierarchical clustering based on the gene signature specifying the two leukemia subtypes showed that the expression profile and the subtype specificity of the primary leukemia were maintained in the xenografts (Fig. 4). The genes most significantly upregulated in matched patient and xenograft samples from *TCF3-HLF*-positive leukemia specified stem cell features (Supplementary Tables 21 and 22). Similar to the case in patient samples, we detected features of mesenchyme-derived tissues in xenografts derived from *TCF3-HLF*-positive ALL. *TCF3-HLF*-positive leukemias and xenografts displayed systematic downregulation of *PAX5* expression to halved levels. Though mono-allelic deletions of *PAX5* were a prominent feature of *TCF3-HLF*-positive ALL, we also saw reduced expression in diploid cases, hinting at alternative molecular mechanisms. The recapitulation of this pattern in the xenograft samples enforces the notion that *TCF3-HLF*-positive leukemia emerges in a specific cellular context with reduced *PAX5* expression (Supplementary Fig. 8). The essential molecular features of *TCF3-HLF*-positive samples were maintained in xenografts, providing a useful model of this disease.

### Drug activity profiling of *TCF3-HLF* and *TCF3-PBX1* ALL


To determine drug sensitivity and resistance profiles, we established ALL cocultures on human mesenchymal stromal cells under serum-free conditions<sup>39</sup>. Both subtypes depend on stroma for survival (Supplementary Fig. 9). *TCF3-PBX1*-positive ALL had a higher proportion of cells in S phase than *TCF3-HLF*-positive ALL on such cultures, reflecting consistent biological differences. By screening 98 bioactive agents, including many agents in clinical development (Supplementary Table 23), on an automated microscopy-based platform, we unambiguously discriminated the two translocations based on their drug sensitivity profiles, using either single (log half maximal inhibitory concentration ( $IC_{50}$ ), Fig. 5a and Supplementary Fig. 10) or multiple response parameters (log  $IC_{50}$ , log 90% effective concentration ( $EC_{90}$ ), log  $EC_{50}$  and

area under the curve (AUC), Fig. 5b and Supplementary Table 24). To capture informative differences, we compared the responses of xenografts derived from *TCF3-HLF*-positive ALL to xenografts derived from other high-risk pre-B and T ALL patients on the same platform (Fig. 5c and Supplementary Table 25). This provided information about the activity range of each drug on the respective ALL subtype. *TCF3-HLF*-positive cases were consistently more resistant to various drugs from the same class, including nucleotide analogs (for example, cytarabine), mitotic spindle inhibitors (for example, vincristine), polo-like and aurora kinase inhibitors. Given the importance of cytarabine and vincristine in standard ALL therapy, the implications of these observations need to be further explored. *TCF3-HLF*-positive ALL was very resistant to dasatinib in this assay, whereas *TCF3-PBX1*-positive ALL responded well. This partly challenges a recent report<sup>40</sup>, which had proposed dasatinib as an alternative for the treatment of these leukemias based on strong *in vitro* activity in one *TCF3-HLF*- and ten *TCF3-PBX1*-positive primary ALL samples. However, *in vivo* studies will be required to verify these differences in drug response, as differences in cell-cycle activity may influence the pattern of response *in vitro*.

*TCF3-HLF*-positive ALL were sensitive to glucocorticoids (prednisone and dexamethasone) and to other drugs that could be relevant for the treatment of resistant ALL, including mTOR inhibitors, anthracyclines, bortezomib, the HSP90 inhibitor AUY922 and panobinostat. However, in spite of the good response of patients with *TCF3-HLF*-positive leukemia to prednisone therapy and the observed responsiveness of *TCF3-HLF*-positive ALL cells to glucocorticoids and anthracyclines that are commonly used in ALL treatment, patients who undergo this treatment relapse. Our transcriptome data suggested that resistance to apoptosis due to high expression of the anti-apoptotic oncoprotein *BCL2* might promote cancer cell survival and constitute a druggable target (Supplementary Fig. 11). *BCL2* is a putative transcriptional target of *TCF3-HLF*<sup>14</sup>. Of note, *PAX5*, commonly deleted in our cohort, normally represses *BCL2* transcription<sup>41</sup>.


### *TCF3-HLF* ALL is extremely sensitive to the *BCL2* antagonist venetoclax

To assess the role of *BCL2* overexpression in *TCF3-HLF*-positive ALL and to provide preclinical evidence for therapeutic activity,



**Figure 4** Major components of the gene expression signature of *TCF3-HLF*- and *TCF3-PBX1*-positive ALL are conserved in patient-derived xenografts. Hierarchical clustering of primary and patient derived xenograft (PDX) ALL samples based on the expression of the 401 genes of the signature defined with primary samples (Fig. 2) shows that xenografts clearly group with their corresponding primary samples.

**Figure 5** Drug activity profiling of *TCF3*-translocated leukemia reveals relevant differences in drug sensitivity. **(a)** Unsupervised clustering based on the drug activity profile of 98 compounds (log IC<sub>50</sub>). Fitted values are provided in **Supplementary Table 24** (absolute IC<sub>50</sub>). Numbers identify the compounds shown in **c**. **(b)** Principal component analysis of the response variables IC<sub>50</sub>, EC<sub>50</sub>, EC<sub>90</sub> and AUC (**Supplementary Table 24**) show *TCF3-PBX1*-positive and *TCF3-HLF*-positive ALL in two distinct clusters. The separation of *TCF3-PBX1*-positive and *TCF3-HLF*-positive ALL is determined by responses to topoisomerases, BCL2 inhibitors, glucocorticoids and antimetabolic agents, which correlate with the first three principal components. **(c)** Selection of drugs based on differences in sensitivity or resistance in *TCF3-PBX1*-positives and *TCF3-HLF*-positives. For comparison, the corresponding drug activity is indicated for 25 additional ALL samples tested on the same platform, including standard risk (SR,  $n = 5$ ), medium risk (MR,  $n = 4$ ) and high risk (HR,  $n = 16$ ) cases (**Supplementary Table 25**). Boxplots extend from the first to the third quartiles (hinges) of the response range for each compound. Whiskers correspond to values from the hinge to the lowest or highest values within 1.5× of the distance between the first and third quartiles, respectively. Drugs with differential activity include docetaxel, paclitaxel, vincristine, AT9283, barasertib, BI2536, torin-1, dasatinib, lestaurtinib and XL228 ( $P \leq 0.05$ ). Drugs which are active across the patients include doxorubicin, idarubicin, mitoxantrone, bortezomib, panobinostat, NVP-AUY922, ABT-199 (venetoclax) and navitoclax. Asterisks indicate drugs currently in clinical use.



we tested the BCL2-targeting drug venetoclax (ABT-199) in our xenograft model (**Fig. 5c**). This BH3-mimetic compound is a highly specific small molecule inhibitor that competes with pro-apoptotic BCL2 family proteins for binding to BCL2, and shifts the balance of pro-death and pro-survival signals inside the cell in favor of cell death<sup>42</sup>. Venetoclax is in clinical development (phase II and III trials) for chronic lymphocytic leukemia and lymphoma, and holds promise for ALL and acute myeloid leukemia.

*TCF3-HLF*-positive ALL samples were more sensitive to venetoclax than *TCF3-PBX1*-positive samples (**Fig. 6a**), which correlated with higher *BCL2* transcript and protein expression (**Fig. 6b**). A two-week treatment course of daily venetoclax administration delayed leukemia progression significantly in ALL xenografts from three different *TCF3-HLF*-positive cases (**Fig. 6c,d**). Treatment of mice in the control arm that reached maximal leukemia burden resulted in very rapid reduction of the leukemic load (**Fig. 6e**). Xenografts from MRD or relapse remained sensitive to venetoclax (**Supplementary Fig. 11**). Profiling of primary cells from two additional cases with refractory ALL confirmed exquisite sensitivity to venetoclax (**Supplementary Fig. 12**). Combined treatment of patient-derived xenografts from patients 6–11 with venetoclax and either vincristine or dexamethasone indicated a potentially

synergistic effect in some of those patients (**Supplementary Fig. 13** and **Supplementary Table 26**). Our data identified BCL2 dependency in *TCF3-HLF* ALL as a druggable target, and illustrate how integration of drug response profiling and molecular genetic analyses can inform the development of innovative treatment strategies in patients with unmet therapeutic needs.

## DISCUSSION

To our knowledge, a long-term cure has never been achieved for patients with *TCF3-HLF*-positive ALL. Our study revealed a recurrent pattern of *TCF3-HLF* accompanied by abnormalities that affect transcriptional regulation of lymphoid development. We found frequent deletions of *PAX5* and *VPREB1* in association with *TCF3-HLF*, but did not detect deletions of Ikaros family members, which are commonly affected in ALL<sup>1,23</sup>. We also uncovered recurrent mutations of the transcription factor TCF3, which acts upstream of *PAX5* in


**Figure 6** The BCL2 antagonist ABT-199 (venetoclax) shows promising anti-leukemic activity in *TCF3-HLF*-positive xenografts.

(a) *In vitro* dose response curves normalized against DMSO-treated controls. (b) Merged absolute reads per kilobase of exon model per million mapped reads (RPKM) values of xenografts derived from the same primary leukemia sample (top) and immunoblot for BCL2 (bottom) in patient-derived xenografts as indicated. Tubulin was used as a loading control. (c,d) *In vivo* response to ABT-199 on *TCF3-HLF*-positive xenografts. Treatment (gray bars) with 100 mg kg<sup>-1</sup> qd ABT-199 (red) or with vehicle control (turquoise) were administered orally for 14 d (6–8 mice per treatment arm). Two treatment courses were administered to xenograft 7a. For survival analysis an event was defined when at least 25% of leukemic cells were detected by FACS (mCD45<sup>+</sup>hCD19<sup>+</sup>hCD45<sup>+</sup>) in the peripheral blood. Differences in the survival of mice receiving ABT-199 or vehicle control were determined by the Mantel-Cox test and verified by the Gehan-Breslow-Wilcoxon test. (e) Mice from the control arm of c,d were treated with ABT-199 when more than 50% of ALL cells were detected in the blood. Mean and s.d. are shown ( $n = 4$ ).

lymphoid development, potentially impairing structural interactions with other transcription cofactors<sup>29</sup>. *PAX5* expression was reduced by twofold in all *TCF3-HLF*-positive cases, underscoring the possibility of an interaction between *TCF3-HLF*, *TCF3* and *PAX5*. *PAX5* is required for B lymphoid lineage commitment and maturation<sup>43</sup>, and is frequently deleted in high-risk ALL with complex patterns of copy number abnormalities<sup>23</sup>. Similarly, deletions in *IKFZ1*, which is required for the development of B and T lymphoid lineages and has additional stem cell-like functions<sup>44</sup>, are detected both in high-risk *BCR-ABL1*-positive and -negative ALL, and in the more favorable *ERG*-altered ALL subtype<sup>45</sup>, but never in *TCF3-HLF*-positive ALL. We also detected focal deletions of *VPREB1* in *TCF3-HLF* ALL, which may lead to a developmental arrest associated with lack of pre-B cell receptor formation and the resulting loss of negative feedback on RAG-mediated recombination<sup>46</sup>. *VPREB1* deletions were present at a similar frequency compared to other high-risk ALLs, such as *BCR-ABL1*-like and *BCR-ABL1*-positive ALL (~30–40% of cases)<sup>47</sup> or hypodiploid ALL (~30%)<sup>24</sup>, associated with poorer overall survival in high-risk pre-B cell ALL patients<sup>24</sup>. However, specific ALL subtypes associated with good prognosis (for example, *ETV6-RUNX1*-positive ALL) also present high frequencies of *VPREB1* deletions<sup>24</sup>, suggesting an important impact of the genomic context<sup>24</sup>. Thus, distinct patterns of association emerge that are likely to reflect important underlying biological mechanisms. Based on our results, we propose that a reduction of *PAX5* gene dosage constitutes a favorable context for the oncogenic activity of *TCF3-HLF*.

As observed for hypodiploid ALL<sup>5</sup> and in subsets of *MLL*-rearranged ALL<sup>48</sup>, we identified mutations in *NRAS*, *KRAS* and *PTPN11* in *TCF3-HLF*-positive ALL. In our xenograft models we detected variable persistence of *NRAS* and a switch to *KRAS* mutations, indicating that RAS mutations are multiclonal and might not be strictly required

for disease progression in *TCF3-HLF*-positive ALL. Indeed, mutations in the RAS pathway are enriched at relapse in ALL<sup>7,30,48</sup> but mostly in a subclonal pattern with losses or switches in *NRAS* and *KRAS* from diagnosis to relapse. These represent secondary events, possibly compensating functional effects of the initiating events. Mutations in the RAS pathway might not represent optimal therapeutic targets, given their volatility and the potential to select for slower-proliferating, more resistant subclones. The *TCF3-HLF* gene expression signature, enriched for components of stem cell and myelomonocytic stages, was very similar among leukemias and maintained in xenografts, specifying additional, novel markers associated with stem cell function, such as *LGR5*, which marks epithelial stem cells<sup>49</sup> and embryonic and fetal hematopoietic progenitor cells in mice<sup>50</sup>. Thus, in analogy to experimental induction of pluripotent stem cells<sup>51,52</sup>, *TCF3-HLF* likely induces a whole set of factors that carry out reprogramming and leukemic transformation in the context of low *PAX5* expression. Deletion of *PAX5* in early B cell progenitors induced dedifferentiation to a state with myeloid and T cell potential<sup>43,53</sup>. Moreover, rescue with low-level expression of *PAX5* in knockout mice generates a stalled biphenotypic B-lymphoid/myeloid state<sup>54</sup>. Together with an activating mutation in *STAT5*, *PAX5* haploinsufficiency initiates ALL in mice<sup>41</sup>. Based on these data, we propose that the initiating *TCF3-HLF* fusion results in severe transcriptional reprogramming with dedifferentiation. The favorable context for transformation is secured through



secondary cooperating lesions in early B cell differentiation genes including *TCF3* and *PAX5*.

A central question remains pertaining to the cell of origin in different ALL subtypes. Our study provides important clues that should be further addressed using disease models. The molecular analysis of the *TCF3-HLF* and *TCF3-PBX1* fusion gene breakpoints indicated that the *TCF3-HLF*, like the *TCF-PBX1* translocation, originates in cells already committed to lymphoid differentiation. Furthermore, we found the associated somatic structural variants to be RAG-mediated, which is comparable to patterns identified recently in *ETV6-RUNX1*-positive ALL, the most frequent pre-B cell ALL subtype, which is consistent with expression of RAG in *TCF3-HLF*-positive ALL<sup>55</sup>. We favor the hypothesis that the *TCF3-HLF* translocation occurs in a B cell progenitor and that the specific lineage context is constrained further in a restricted developmental stage by additional mutations. The detection of *TCF3-HLF* being restricted to leukemic cells supports this idea, although initiation in a more immature compartment cannot be formally excluded.

The molecular landscapes of *TCF3-HLF*-positive ALL were largely conserved in xenografts, providing a valuable, well characterized, model for preclinical testing. Drug activity profiling revealed that *TCF3-HLF*-positive cases were more resistant to several standard ALL drugs, such as nucleotide analogs (for example, cytarabine) and mitotic spindle inhibitors (for example, vincristine). We detected activity for other relevant drug classes, such as mTOR inhibitors, the proteasome inhibitor bortezomib, the HSP90 inhibitor AUY922 and the HDAC inhibitor panobinostat. The BCL2 inhibitor venetoclax (ABT-199)<sup>42</sup> was highly active in all *TCF3-HLF*-positive cases analyzed, which we confirmed using primary ALL cells from two additional cases with refractory disease. These results refine data obtained using the broader spectrum BH3 mimetic ABT-737 in *TCF3-HLF*-positive cell lines<sup>14</sup>. Given the activity of venetoclax also in other ALL subsets including immature T cell ALL (refs. 56,57 and our own unpublished data) and the lack of on-target thrombocytopenia caused by ABT-737, venetoclax should be explored for experimental therapy in refractory ALL in selected cases based on such functional data. Thus integrated genomic and functional analyses of *TCF3-HLF*-positive ALL provide insight into the molecular context and associated components and offer unprecedented possibilities to investigate new agents for the treatment of these children who currently lack effective therapeutic options.

**URLs.** Information on the two image processing programs used for *in vitro* drug screening and automated microscopy can be found at <http://acc.ethz.ch/>.

## METHODS

Methods and any associated references are available in the [online version of the paper](#).

**Accession codes.** Sequencing data are available from the public POPGEN repository (2015-UFO-NG-1; Christian Albrechts University, Kiel) upon written request accompanied by a positive internal review board vote for research addressing leukemia-related questions. Sequencing data transfer can proceed upon positive review and signing of a material transfer agreement.

## ACKNOWLEDGMENTS

We thank all participants and personnel involved in the clinical trials in Austria, France, Germany, United Kingdom and Switzerland. We thank T. Radimerski and Novartis for providing essential compounds. We thank the Leukaemia & Lymphoma Research (LLR) Childhood Leukaemia Cell Bank in the UK for

providing primary patient samples. This work was supported by the German Federal Office for Radiation Protection (grant St.Sch. 3611S70014), by the Swiss National Research Foundation SNF 310030-133108, the foundation 'Kinderkrebsforschung Schweiz', the 'Krebsliga Zurich', the Sasselva Foundation, the Fondation Panacée, the clinical research focus program 'Human Hemato-Lymphatic Diseases' of the University of Zurich, the Deutsche Forschungsgemeinschaft (DFG), Clusters of Excellence 'Inflammation at Interfaces', the EU Seventh Framework Program (FP7/2007-2013, grant 262055, ESGI; FP7-HEALTH-F2-2011 grant 261474, ENCCA; ERA-Net Transcan, Validation of biomarkers for personalized cancer medicine, TRANSCALL; Health-F2-2010 grant 260791, EUROCANPLATFORM), the 'Katharina Hardt Stiftung', the 'Deutsche José Carreras Leukämie-Stiftung', the 'Madeleine Schickedanz-Kinderkrebs-Stiftung', the 'Deutsche Krebshilfe – Dr. Mildred Scheel Stiftung' (grants 108613, 102588 and 108588), the Foundation of Experimental Biomedicine in Zurich, the Max Planck Society, and the 'Verein für krebskranke Kinder Hannover e.V.'. We thank A. Dehos, B. Grosche, T. Jung, W. Weiss and G. Ziegelberger, German Federal Office for Radiation Protection, as well as B. Heinzow, State Office for Social Services of Schleswig-Holstein, and A. Böttger, German Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety for their support and critical discussions. We are grateful for the excellent technical assistance offered by the sequencing team of the Department of Vertebrate Genomics of the Max Planck Institute for Molecular Genetics (Berlin) and by the team of the Genomics Core facility of the European Molecular Biology Laboratory. We thank K. Alemazkour for excellent technical assistance regarding whole exome sequencing at the Department of Pediatric Oncology, Hematology and Clinical Immunology (Düsseldorf, Germany). We thank N. Forgo, Institute for Legal Informatics, Leibniz University Hannover, and H.-D. Tröger, Hannover Medical School, for legal and ethical counselling.

## AUTHOR CONTRIBUTIONS

A. Borkhardt, A.F., J.O.K., J.-P.B., M.-L.Y. and M. Stanulla jointly designed the project. A. Baruchel, A.V., A.V.M., C.C., C.P.K., F.N., G.B., G.C., G.t.K., H.C., M. Schrappe, M. Stanulla, N.v.d.W., O.A.H., C.E. and R.P.-G. provided samples or clinical data. A. Borkhardt, A.C.M., A.F., A.V., C.E., G.H.-S., H.L., J.-P.B., J.O.K., J.T., M.D., M.F., M.-L.Y., M.P.D., M. Schrappe, M. Stanulla, M. Zimmermann, O.A.H., P.R. and T.Z. contributed reagents, materials or analysis tools. A.M.S., B.B., B.M., C.E., C.L.W., H.-J.W., J.I.H., J.-P.B., M.F., M.G., S. Sungalee and U.F. designed experiments. A.M.S., A.R., B.B., B.R., B.S., B.S.P., C.E., C.K., C.L.W., D.D., D.S., H.-J.W., J.T., K.H., L.Z., M.G., M.R., M. Zaliova, M. Sultan, P.K., S.E., S. Sungalee, T.B., U.F. and V.F. performed experiments. A.R., B.S., B.S.P., C.E., C.K., C.L.W., D.S., E.E., J.I.H., H.-J.W., M.G., M.P.D., M.F., N.B., S.G., G.H.-S., P.H., P.K., M.-L.Y., M.R., M. Stanulla, M. Schütte, M. Zaliova, S. Sungalee, T.R., U.F. and V.A. analyzed data. A. Borkhardt, A.C.M., A.F., B.B., H.L., J.-P.B., J.O.K., M.D., M.F., M.-L.Y., M. Stanulla, O.H., R.T. and S. Schreiber, U.F. supervised research. A.R., C.L.W., D.S., H.-J.W., M.F., M.P.D., M. Stanulla, P.K., S. Sungalee, T.R. and U.F. prepared tables and figures. J.-P.B., M. Stanulla and M.-L.Y. wrote the manuscript. A. Borkhardt, A.F., A.R., A.V.M., H.-J.W., J.O.K., M.F., M.P.D., O.H., S.H., S. Sungalee, T.R. and U.F. contributed to the writing of the manuscript. All authors critically reviewed the manuscript for its content.

## COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Mullighan, C.G. *et al.* Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* **446**, 758–764 (2007).
- Russell, L.J. *et al.* Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. *Blood* **114**, 2688–2698 (2009).
- Mullighan, C.G. *et al.* Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. *Nat. Genet.* **41**, 1243–1246 (2009).
- Hertzberg, L. *et al.* Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. *Blood* **115**, 1006–1017 (2010).
- Holmfeldt, L. *et al.* The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nat. Genet.* **45**, 242–252 (2013).
- Zhang, J. *et al.* Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood* **118**, 3080–3087 (2011).
- Irving, J. *et al.* Ras pathway mutations are highly prevalent in relapsed childhood acute lymphoblastic leukaemia, may act as relapse-drivers and confer sensitivity to MEK inhibition. *Blood* **124**, 3420–3430 (2014).

8. Inaba, H., Greaves, M. & Mullighan, C.G. Acute lymphoblastic leukaemia. *Lancet* **381**, 1943–1955 (2013).
9. Kwon, K. *et al.* Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. *Immunity* **28**, 751–762 (2008).
10. Felice, M.S. *et al.* Prognostic impact of t(1;19) TCF3–PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Munster-based protocols. *Leuk. Lymphoma* **52**, 1215–1221 (2011).
11. Hunger, S.P., Ohyashiki, K., Toyama, K. & Cleary, M.L. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. *Genes Dev.* **6**, 1608–1620 (1992).
12. Inukai, T. *et al.* Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. *Leukemia* **21**, 288–296 (2007).
13. Boller, S. & Grosschedl, R. The regulatory network of B-cell differentiation: a focused view of early B-cell factor 1 function. *Immunol. Rev.* **261**, 102–115 (2014).
14. de Boer, J. *et al.* The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors. *Leukemia* **25**, 321–330 (2011).
15. Hirose, K. *et al.* Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). *Blood* **116**, 962–970 (2010).
16. Inukai, T. *et al.* SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. *Mol. Cell* **4**, 343–352 (1999).
17. Inoue, A. *et al.* Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. *Cancer Cell* **2**, 279–288 (2002).
18. Honda, H. *et al.* Expression of E2A-HLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest, and development of acute lymphoblastic leukemia. *Blood* **93**, 2780–2790 (1999).
19. Smith, K.S., Rhee, J.W., Naumovski, L. & Cleary, M.L. Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice. *Mol. Cell. Biol.* **19**, 4443–4451 (1999).
20. Hunger, S.P. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. *Blood* **87**, 1211–1224 (1996).
21. Wiemels, J.L. *et al.* Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A–PBX1 fusion in childhood acute lymphoblastic leukemia. *Proc. Natl. Acad. Sci. USA* **99**, 15101–15106 (2002).
22. Tsai, A.G. *et al.* Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. *Cell* **135**, 1130–1142 (2008).
23. Moorman, A.V. *et al.* A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. *Blood* **124**, 1434–1444 (2014).
24. Mangum, D.S. *et al.* VPBEB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. *Leukemia* **28**, 216–220 (2014).
25. Waanders, E. *et al.* The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. *PLoS Genet.* **8**, e1002533 (2012).
26. Tijchon, E., Havinga, J., van Leeuwen, F.N. & Scheijen, B. B-lineage transcription factors and cooperating gene lesions required for leukemia development. *Leukemia* **27**, 541–552 (2013).
27. Balbin, O.A. *et al.* Reconstructing targetable pathways in lung cancer by integrating diverse omics data. *Nat. Commun.* **4**, 2617 (2013).
28. Wright, D.D., Sefton, B.M. & Kamps, M.P. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. *Mol. Cell. Biol.* **14**, 2429–2437 (1994).
29. Schmitz, R. *et al.* Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature* **490**, 116–120 (2012).
30. Ma, X. *et al.* Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. *Nat. Commun.* **6**, 6604 (2015).
31. Laurenti, E. *et al.* The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. *Nat. Immunol.* **14**, 756–763 (2013).
32. Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J.P. GSEA-P: a desktop application for Gene Set Enrichment Analysis. *Bioinformatics* **23**, 3251–3253 (2007).
33. Schepers, A.G. *et al.* Lineage tracing reveals Lgr5<sup>+</sup> stem cell activity in mouse intestinal adenomas. *Science* **337**, 730–735 (2012).
34. Akahane, K. *et al.* Specific induction of CD33 expression by E2A-HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor. *Leukemia* **24**, 865–869 (2010).
35. Nissim, S. *et al.* Prostaglandin E2 regulates liver versus pancreas cell-fate decisions and endodermal outgrowth. *Dev. Cell* **28**, 423–437 (2014).
36. Schmitz, M. *et al.* Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. *Blood* **118**, 1854–1864 (2011).
37. Bonapace, L. *et al.* Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. *J. Clin. Invest.* **120**, 1310–1323 (2010).
38. Stark, Z. *et al.* Two novel germline KRAS mutations: expanding the molecular and clinical phenotype. *Clin. Genet.* **81**, 590–594 (2012).
39. Boutter, J. *et al.* Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. *Oncotarget* **5**, 11501–11512 (2014).
40. Bicocca, V.T. *et al.* Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. *Cancer Cell* **22**, 656–667 (2012).
41. Heltemes-Harris, L.M. *et al.* Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. *J. Exp. Med.* **208**, 1135–1149 (2011).
42. Souers, A.J. *et al.* ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat. Med.* **19**, 202–208 (2013).
43. Rolink, A.G., Nutt, S.L., Melchers, F. & Busslinger, M. Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors. *Nature* **401**, 603–606 (1999).
44. Joshi, I. *et al.* Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. *Nat. Immunol.* **15**, 294–304 (2014).
45. Clappier, E. *et al.* An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. *Leukemia* **28**, 70–77 (2014).
46. Grawunder, U. *et al.* Down-regulation of RAG1 and RAG2 gene expression in preB cells after functional immunoglobulin heavy chain rearrangement. *Immunity* **3**, 601–608 (1995).
47. Den Boer, M.L. *et al.* A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. *Lancet Oncol.* **10**, 125–134 (2009).
48. Andersson, A.K. *et al.* The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. *Nat. Genet.* **47**, 330–337 (2015).
49. Barker, N. *et al.* Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* **449**, 1003–1007 (2007).
50. Liu, D. *et al.* Leucine-rich repeat-containing G-protein-coupled Receptor 5 marks short-term hematopoietic stem and progenitor cells during mouse embryonic development. *J. Biol. Chem.* **289**, 23809–23816 (2014).
51. Riddell, J. *et al.* Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. *Cell* **157**, 549–564 (2014).
52. Sandler, V.M. *et al.* Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. *Nature* **511**, 312–318 (2014).
53. Urbánek, P., Wang, Z.Q., Fetka, I., Wagner, E.F. & Busslinger, M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. *Cell* **79**, 901–912 (1994).
54. Simmons, S. *et al.* Biphentotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development. *Blood* **120**, 3688–3698 (2012).
55. Papaemmanuil, E. *et al.* RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. *Nat. Genet.* **46**, 116–125 (2014).
56. Peirs, S. *et al.* ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. *Blood* **124**, 3738–3747 (2014).
57. Chonghaile, T.N. *et al.* Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. *Cancer Discov.* **4**, 1074–1087 (2014).
58. El Omari, K. *et al.* Structural basis for LMO2-driven recruitment of the SCL: E47bHLH heterodimer to hematopoietic-specific transcriptional targets. *Cell Rep.* **4**, 135–147 (2013).

Ute Fischer<sup>1,2,6</sup>, Michael Forster<sup>2,26</sup>, Anna Rinaldi<sup>3,26</sup>, Thomas Risch<sup>4,26</sup>, Stéphanie Sungalee<sup>5,26</sup>, Hans-Jörg Warnatz<sup>4,26</sup>, Beat Bornhauser<sup>3</sup>, Michael Gombert<sup>1</sup>, Christina Kratsch<sup>6</sup>, Adrian M Stütz<sup>5</sup>, Marc Sultan<sup>4</sup>, Joelle Tchinda<sup>3</sup>, Catherine L Worth<sup>4</sup>, Vyacheslav Amstislavskiy<sup>4</sup>, Nandini Badarinarayan<sup>2</sup>, André Baruchel<sup>7</sup>, Thies Bartram<sup>8</sup>, Giuseppe Basso<sup>9</sup>, Cengiz Canpolat<sup>10</sup>, Gunnar Cario<sup>8</sup>, Hélène Cave<sup>11</sup>, Dardane Dakaj<sup>3</sup>, Mauro Delorenzi<sup>12,13</sup>, Maria Pamela Dobay<sup>13</sup>, Cornelia Eckert<sup>14</sup>, Eva Ellinghaus<sup>2</sup>, Sabrina Eugster<sup>3</sup>, Viktoras Frismantas<sup>3</sup>, Sebastian Ginzel<sup>1,15</sup>, Oskar A Haas<sup>16</sup>, Olaf Heidenreich<sup>17</sup>, Georg Hemmrich-Stanisak<sup>2</sup>, Kebria Hezaveh<sup>1</sup>, Jessica I Höll<sup>1</sup>, Sabine Hornhardt<sup>18</sup>, Peter Husemann<sup>1</sup>,

Priyadarshini Kachroo<sup>2</sup>, Christian P Kratz<sup>19</sup>, Geertruy te Kronnie<sup>9</sup>, Blerim Marovca<sup>3</sup>, Felix Niggli<sup>3</sup>, Alice C McHardy<sup>6</sup>, Anthony V Moorman<sup>17</sup>, Renate Panzer-Grümayer<sup>16</sup>, Britt S Petersen<sup>2</sup>, Benjamin Raeder<sup>5</sup>, Meryem Ralser<sup>4</sup>, Philip Rosenstiel<sup>2</sup>, Daniel Schäfer<sup>1</sup>, Martin Schrappe<sup>8</sup>, Stefan Schreiber<sup>2</sup>, Moritz Schütte<sup>20</sup>, Björn Stade<sup>2</sup>, Ralf Thiele<sup>15</sup>, Nicolas von der Weid<sup>21</sup>, Ajay Vora<sup>22</sup>, Marketa Zaliova<sup>19,23</sup>, Langhui Zhang<sup>1,24</sup>, Thomas Zichner<sup>5</sup>, Martin Zimmermann<sup>19</sup>, Hans Lehrach<sup>4,20,25</sup>, Arndt Borkhardt<sup>1,27</sup>, Jean-Pierre Bourquin<sup>3,27</sup>, Andre Franke<sup>2,27</sup>, Jan O Korbel<sup>5,27</sup>, Martin Stanulla<sup>19,27</sup> & Marie-Laure Yaspo<sup>4,27</sup>

<sup>1</sup>Clinic for Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. <sup>2</sup>Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, Kiel, Germany. <sup>3</sup>Pediatric Oncology, Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland. <sup>4</sup>Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany. <sup>5</sup>European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany. <sup>6</sup>Department of Algorithmic Bioinformatics, Heinrich Heine University, Düsseldorf, Germany. <sup>7</sup>Department of Pediatric Hemato-Immunology, Hôpital Robert Debré and Paris Diderot University, Paris, France. <sup>8</sup>Department of Pediatrics, Christian Albrechts University of Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany. <sup>9</sup>Department of Pediatrics, Laboratory of Pediatric Hematology/Oncology, University of Padova, Padova, Italy. <sup>10</sup>Department of Pediatrics, Acibadem University Medical School, Ataşehir, Istanbul, Turkey. <sup>11</sup>Department of Genetics, Hôpital Robert Debré and Paris Diderot University, Paris, France. <sup>12</sup>Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland. <sup>13</sup>Swiss Institute for Bioinformatics (SIB), Lausanne, Switzerland. <sup>14</sup>Pediatric Hematology and Oncology, Charité University Hospital, Berlin, Germany. <sup>15</sup>Department of Computer Science, Bonn Rhine Sieg University of Applied Sciences, Sankt Augustin, Germany. <sup>16</sup>Children's Cancer Research Institute, Vienna, Austria. <sup>17</sup>Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom. <sup>18</sup>Federal Office for Radiation Protection, Oberschleissheim, Germany. <sup>19</sup>Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany. <sup>20</sup>Alacris Theranostics GmbH, Berlin, Germany. <sup>21</sup>Universitäts-Kinderspital beider Basel (UKBB), Basel, Switzerland. <sup>22</sup>Sheffield Children's Hospital, Sheffield, United Kingdom. <sup>23</sup>Childhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, Second Faculty of Medicine, Charles University Prague, Prague, Czech Republic. <sup>24</sup>Department of Hematology, Union Hospital, Fujian Medical University, Fuzhou, China. <sup>25</sup>Dahlem Centre for Genome Research and Medical Systems Biology, Berlin, Germany. <sup>26</sup>These authors contributed equally to this work. <sup>27</sup>These authors jointly supervised this work. Correspondence should be addressed to M.S. ([stanulla.martin@mh-hannover.de](mailto:stanulla.martin@mh-hannover.de)) or J.-P.B. ([jean-pierre.bourquin@kispi.uzh.ch](mailto:jean-pierre.bourquin@kispi.uzh.ch)).

## ONLINE METHODS

**Study individuals and sample selection.** Samples and associated clinical information from patients included in sequencing and validation analyses were collected from different countries within the International BFM Study Group (I-BFM-SG). All patients were enrolled in multicenter trials on treatment of pediatric ALL conducted by individual member groups of the I-BFM-SG: the AIEOP-BFM study group (Austria, Germany, Italy and Switzerland), the FRALLE study group (France) and the United Kingdom (UK) National Cancer Research Institute (NCRI) Childhood Cancer and Leukemia Group<sup>59,60</sup>. All treatment trials were approved by the respective national institutional review boards, and informed consent for the use of spare specimens for research was obtained from study individuals, parents or legal guardians. The specific research project reported here was approved by the Ethics Committee of the Medical Faculty of the Christian Albrechts University, Kiel, Germany (vote D508/13). Depending on consent and availability of samples, all enrolled patients positive for the rare *TCF3-HLF* gene fusion were included. These patients were matched with *TCF3-PBX1*-positive patients.

**Cell isolation and nucleic acid purification.** Mononuclear cells were isolated by Ficoll-Paque gradient centrifugation (Pharmacia) from bone marrow or peripheral blood samples followed by extraction of nucleic acids according to standardized protocols using Qiagen DNA Blood Kits (Qiagen) for DNA and Qiagen RNeasy columns (Qiagen) for RNA. The quantity of nucleic acids was determined by spectrophotometry. DNA quality was assessed visually by inspection of agarose gel electrophoresis while RNA integrity was evaluated by using the Bioanalyzer 2100 (Agilent). Nucleic acids isolated from bone marrow aspirates collected in morphological remission served as individual germ-line surrogates/references.

**Sequencing. Whole genome sequencing.** For structural variants, Illumina v2 mate-pair libraries with 5 kbp insert size and  $2 \times 101$  bp reads were prepared from 10  $\mu$ g of DNA and sequenced on the Illumina HiSeq 2000 platform (Illumina) to obtain a physical coverage of 30 $\times$ . For copy number alterations, breakpoints and short variants (SNVs, short indels), Illumina TruSeq paired-end libraries with  $2 \times 101$  bp reads were prepared from 1  $\mu$ g of DNA and sequenced on HiSeq 2000/2500 instruments to a coverage of 40 $\times$  for reference samples and 80 $\times$  for tumor samples.

**Whole exome sequencing.** To increase the sensitivity of detecting short variants in coding regions, 1  $\mu$ g of DNA each from the diagnostic leukemic and a corresponding remission sample of patients was used for whole exome sequencing. Whole exome capture employed a TruSeq enrichment kit (Illumina) and paired-end libraries with  $2 \times 101$  bp reads on a HiSeq 2500 according to the manufacturer's protocol.

**Whole transcriptome sequencing.** Illumina TruSeq custom stranded paired-end libraries with  $2 \times 51$  bp reads were prepared from 1  $\mu$ g RNA using the Ribo-Zero Gold Kit (Epicentre) and sequenced on a HiSeq 2000 with a loading of one library per lane.

**Sanger sequencing validation.** Structural variant breakpoints from whole-genome sequencing approaches and SNVs from exome sequencing were validated by Sanger sequencing.

**Targeted sequencing of *TCF3* and *RAS* pathway candidate genes.** *TCF3* binding domain (E47 isoform, exon 18) mutations were screened for in 1,033 ALL patients using Sanger sequencing. Primer sequences are listed in **Supplementary Table 27**. Sanger sequencing was also applied for validation of relative absence of *RAS* pathway mutations in 24 *TCF3-PBX1*-positive ALL samples. The latter analysis included *KRAS* exon 1, *NRAS* exons 1 and 2, *FLT3* exons 14 and 20, *PTPN11* exons 3 and 13, and was conducted as described<sup>61</sup>.

**Multiplex ligation-dependent probe amplification.** Detection of genomic aberrations in B cell differentiation-associated and other genes frequently deleted in ALL (*PAX5*, *IKZF1*, *ETV6*, *RB1*, *BTG1*, *EBF1*, *CDKN2A*, *CDKN2B* and *P2RY8-CRLF2*) were investigated by the Multiplex Ligation-dependent Probe Amplification (MLPA) assay SALSA p335 kit (MRC-Holland) using 125 ng of genomic DNA. The assays were performed according to the manufacturer's protocol as described<sup>62</sup>. An intensity ratio between 0.75 and 1.3 was considered to represent normal copy number, a ratio between 0.25 and 0.75 was considered a monoallelic deletion and a ratio <0.25, a biallelic deletion.

**Bioinformatics analysis. DNA data processing.** DNA reads were aligned to the human reference genome hg19 (downloaded from the UCSC Genome browser) using Elandv2 (ref. 63; mate pairs) and BWA<sup>64</sup> (paired ends). For xenograft samples, the human DNA reads were deconvoluted after mapping to a combined reference consisting of human hg19 and mouse mm9.

**Structural variant detection.** Structural variants were detected using DELLY<sup>65</sup> and BIC-seq<sup>66</sup> (DNA data) and TopHat2 (ref. 67) /deFuse<sup>68</sup> (RNA data).

**SNV detection.** Somatic protein-changing SNVs were detected using established pipelines incorporating GATK<sup>69</sup>, MuTect<sup>70</sup>, pibase<sup>71</sup>, Picard, SAMtools<sup>72</sup> and VarScan2 (ref. 73).

**Indel detection.** Somatic indels in coding regions were detected using SAMtools followed by Dindel<sup>74</sup>.

**Transcriptome data analysis.** RNA reads were aligned to hg19 using BWA and SAMtools and used for integrated data analysis. For xenograft samples, the human RNA reads were deconvoluted after mapping to a combined reference consisting of human hg19 and mouse mm9. Mapped reads were annotated using Ensembl v.70. Gene expression levels were quantified in reads per kilobase of exon model per million mapped reads (RPKM)<sup>75</sup>. RPKM calculation and differential gene expression (DGE) analysis was performed using the R package edgeR<sup>76</sup>. To identify DGE between ALL subtypes, and between leukemia and remission the following set-up was performed: *TCF3-PBX1* vs. *TCF3-HLF* (comparison 1), *TCF3-PBX1* vs. remission (comparison 2), *TCF3-HLF* vs. remission (comparison 3). The results were filtered by fold change (FC,  $|\log_2(\text{FC})| \geq 1$ ) and false discovery rate (FDR,  $\text{FDR} \leq 0.001$ ). The final list of 401 genes was created by combining the intersection between comparison 1 and comparison 2 as well as between comparison 1 and comparison 3. The functional analyses of gene lists were done using gene set enrichment analysis (GSEA)<sup>77</sup> and the Genomatix genome analyzer (v. 3.00801; Genomatix Software GmbH). The GeneRanker tool in Genomatix was used to test for enriched gene sets, which were based on gene-tissue annotations obtained by text mining<sup>78</sup>. For GSEA, protein-coding genes were filtered by a minimum expression of 1 RPKM in at least four samples among the primary pre-B cell ALLs. The remaining 11,315 genes were tested for DGE between the ALL subtypes using edgeR. The provided FDR and fold-change values were used to obtain a ranking score to measure the degree of differential expression between the ALL subtype. A pre-ranked classic GSEA was performed using the ranking score, a gene set permutation and a  $\text{FDR} \leq 0.02$ . The analysis included gene sets for hematopoietic stages<sup>31</sup> and signatures from MsigDB<sup>77</sup> pathways (C2): KEGG, BIOCARTA, REACTOME; curated oncogenic signatures (C6); human immunologic signatures (C7).

**In silico transcription factor binding site (TFBS) analysis.** TFBSs in promoter regions of genes (2 kbp upstream region) corresponding to the specific transcriptome signatures of *TCF3-PBX1*- and *TCF3-HLF*-positive ALL, respectively, were analyzed using the Genomatix Genome Analyzer (v3.10124). Based on a matrix of known TFBS motifs, the software tool predicted TFBSs in the investigated promoters and compared their frequency against (i) the background of TFBSs in the promoter regions of all known protein-coding genes in the Ensembl database (v.70, 22864 genes) and (ii) the background of TFBSs in the whole genome. A Z score was calculated based on the TFBS frequency in the investigated promoters and the expected frequency and s.d. were estimated from the background<sup>79</sup>. The resulting lists were filtered by the Z scores based on the two backgrounds ( $|\text{genomic } Z| \geq 2$ , promoter  $Z \geq 2$ ). TFBSs overrepresented in genes upregulated in both *TCF3-PBX1*- and *TCF3-HLF*-positive ALL were filtered out, to retain only TFBS specifically enriched in the respective subtypes.

**Integrated data analysis.** SNVs and indels were orthogonally validated by integrating genome, exome and transcriptome data of patients and xenografts, and further confirmed by Sanger sequencing. Structural variants were validated by integrating whole genome paired-end and mate-pair data and whole-transcriptome data, and finally by Sanger sequencing. Ensembl v.70 and ANNOVAR<sup>80</sup> were used to annotate the variants. Silent variants and known germline variants in the 1000 Genomes Project<sup>81</sup> population data, in 136 North German healthy controls (publicly available through GrabBlur<sup>82</sup>), or in the International Cancer Genome Consortium's internal healthy controls were eliminated. All final somatic non synonymous variants were inspected using IGV<sup>83</sup>.

**Preclinical characterization. Xenograft model.** Animal experiments were approved by the veterinary office of the Canton of Zurich, Switzerland. Approval for experiments with human samples in the mouse xenograft model was obtained from the ethics commission of the Canton Zurich (approval number 2014-0383). In brief, primary ALL cells were recovered from cryopreserved samples and transplanted intraperitoneally to NSG mice as previously described<sup>36</sup>. Mice were 5–10 weeks old; both males and females were randomly used. Leukemia progression was monitored by flow cytometry with rat anti-mouse CD45 (eFluor450, clone 30-F11, REF 48-451-82, eBioscience), mouse anti-human CD45 (Alexa Flour 647, clone HI30, REF 304018, BioLegend), and mouse anti-human CD19 (PE, clone HIB19, REF 302208, BioLegend). ALL cells recovered from spleens of NSG mice were used for molecular characterization *in vitro* and *in vivo* experiments.

**Immunophenotyping.** Immunophenotyping of patient and xenograft-amplified human ALL cells after recovery from the spleen was performed as described before<sup>84</sup>. All included xenograft samples consisted of at least 95% human leukemic cells.

**Cell culture.** Human hTERT immortalized primary bone marrow mesenchymal stromal cells (MSC; provided by D. Campana, St. Jude Children's Research Hospital, Memphis, USA) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS; L-glutamine (2 mM), penicillin/streptomycin (P/S; 100 IU/ml) and hydrocortisone (1  $\mu$ M). Xenograft-amplified human ALL cells were co-cultured on MSC in AIM V medium (Gibco by Life Technologies) at a ratio of 10:1. All cultured cells were kept in the incubator at 37 °C, 5% CO<sub>2</sub>. For cryopreservation, cells were frozen in heat-inactivated FBS with 10% dimethylsulfoxide and subsequently stored in liquid nitrogen.

**Cell viability assay.** MSCs were seeded in 24-well plates at a number of 50,000 cells per well in RPMI 1640 medium (10% heat-inactivated FBS). After 24 h primary ALL cells were thawed and seeded as suspension culture alone or in co-culture with MSCs at a number of 400,000 cells per well in AIM-V medium. Three days later, ALL cells were collected from monoculture or co-culture by scraping and stained with 7-AAD (BD Pharmingen). Cell viability (7-AAD negative population) was measured by FACS using counting beads (SPHERO Accu Count Blanc Particles, Spherotech Inc.) for cell counts normalization. Viabilities shown are average viabilities of duplicate wells (normalized to input) and s.d.

**Cell cycle assay.** MSCs were seeded in 96-well tissue culture plates at a concentration of 10,000 cells per well in 100  $\mu$ l AIM-V medium. After 24 h ALL cells were added at a concentration of 100,000 cells per well in 90  $\mu$ l AIM-V. The Click-iTEdu Alexa Fluor 488 Flow Cytometry Assay Kit (Life Technologies) in combination with propidium iodide was used to measure proliferation and to identify the different phases of the cell cycle on days 1 and 3. Co-cultured cells were incubated with EdU (10  $\mu$ M) for 20 h before cell cycle read-out with flow cytometry. The cell cycle assay was performed in triplicate, and at least two independent experiments were performed for each sample. Similar variances were obtained between the groups that were statistically compared.

**In vitro drug screening and automated microscopy.** MSCs were seeded in 384-well plates at a concentration of 2,500 cells per well in 30  $\mu$ l AIM-V medium. After 24 h, ALL cells were added at a concentration of 25,000–30,000 cells per well in 27.5  $\mu$ l AIM-V. Drugs were added as single agents after an additional 24 h using the pipetting robot epMotion 5070 (Eppendorf). Drug response was normalized to ALL cells treated with the drug vehicle alone. Experiments were performed in duplicate in five different dilutions (1, 10, 100, 1,000 and 10,000 nM). For two samples comparable results were obtained in two independent drug screening experiments. After 72 h or 96 h of drug incubation, cells were stained using the CyQUANT direct cell proliferation assay (Life technologies). 20  $\mu$ l staining mix (AIM V medium, CyQUANT (1:300), repressor (1:20)) was added into each well followed by an incubation time of 1 h at 37 °C, 5% CO<sub>2</sub>. Subsequently, automated imaging was performed using the ImageXpress Micro microscope (Molecular Devices) equipped with a CoolSNAP HQ camera (Photometrics) and a 10 $\times$  plan fluor objective with 0.3 NA (Nikon). Nine images were taken per well, covering 50% of each well and captured employing

the MetaXpress software (Molecular Devices). Images were processed using CellProfiler software (Broad Institute). Cells were classified and counted using the Advanced Cell Classifier software. This software uses random forest classification to assign ALL cells properly.

**Immunoblot.** Whole cell extracts were prepared from 1  $\times$  10<sup>6</sup> cells using radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris-Cl pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA pH 8.0, 0.1% SDS) supplemented with Complete mini protease inhibitor cocktail (Roche Life Science) for 20 min on ice, sonicated as necessary, and diluted with SDS loading buffer (250 mM Tris pH 6.8, 4% SDS, 0.02% bromophenol blue, 40% glycerol, 4% (vol/vol)  $\beta$ -mercaptoethanol). After SDS-PAGE, proteins were blotted onto nitrocellulose membranes. Membranes were blocked in 5% non-fat dry milk and incubated with primary Bcl-2 (clone 124; Dako) and tubulin antibodies diluted 1:1,000 in milk. Horseradish peroxidase-labeled anti-mouse antibodies were used for signal detection with chemiluminescence substrate and direct scanning.

**In vivo experiments.** ALL cells were recovered from cryopreserved xenograft samples, and per thawed sample 12 to 16 mice were transplanted with 1,000,000 cells per mouse. After three days, randomized cohorts were treated with 100 mg/kg of ABT-199 (ABBVIE) or vehicle control with 6 to 8 mice per treatment arm<sup>85</sup>. ABT-199 or vehicle control were administered orally daily for two weeks. Mice of the ABT-199 group transplanted with sample 7a were additionally treated with a second block (100 mg/kg of ABT-199 for 14 d) starting at day 66, when the frequency of circulating leukemia cells started to increase again. Follow-up of circulating leukemia cells was performed every 7 d by flow cytometry with rat anti-mouse CD45, mouse anti-human CD45, and mouse anti-human CD19; frequency of leukemia cells as ratio of mCD45<sup>+</sup>hCD45<sup>+</sup>hCD19<sup>+</sup> count to total lymphocytes. The investigator was blinded to the group allocation during the assessment of outcome. To evaluate the ability of ABT-199 to decrease tumor burden, four mice in the control group were treated when the frequency of leukemia cells in the peripheral blood was equal or higher than 50%. Follow-up of circulating leukemia cells was performed every 4–7 d. *In vivo* experiments were terminated when the frequency of circulating leukemia cells reached 50% or earlier if the mice showed abnormal behavior. One *in vivo* experiment was performed per each sample.

**Statistical analysis.** Differences in the distribution of categorical variables among patient subsets were analyzed using Fisher's exact or chi-squared test. Comparisons of continuous variables between groups were performed by *t*-test or Mann-Whitney *U* test.

Drug responses were evaluated by fitting DMSO-normalized response data with the four-parameter log-logistic function of the form:

$$f(x) = \text{base} + \frac{E_{\text{max}} - \text{base}}{1 + (x_{1/2}/x)^{\text{Coeff}}}$$

as implemented in the drc package of R (version 2.3-96). Outliers were detected and removed before curve fitting using Bayesian change point analysis<sup>25</sup> (R package bcp, version 3.0.1). Non-convergent cases (for example, drugs with no activity) were identified based on linear fit parameters. Hierarchical clustering was performed to group patients according to their drug-response profiles (R package gplots version 2.14.2). Drugs with differential activity in patients with *TCF3-PBX1*- compared to *TCF3-HLF*-positive ALL were identified using a *t*-test ( $P \leq 0.05$ ). In *in vivo* experiments, 25% of circulating leukemia cells or termination of the experiment if 25% of leukemia was not reached were considered as an event in the Kaplan-Meier analysis. For sample 9a, 50% was used because of the rapid engraftment. Differences in the survival of mice receiving ABT-199 or vehicle control were determined by the Mantel-Cox test and verified by the Gehan-Breslow-Wilcoxon test.

59. Conter, V. *et al.* Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood* **115**, 3206–3214 (2010).

60. Harrison, C.J. *et al.* Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. *Br. J. Haematol.* **151**, 132–142 (2010).
61. Case, M. *et al.* Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. *Cancer Res.* **68**, 6803–6809 (2008).
62. Dörge, P. *et al.* IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. *Haematologica* **98**, 428–432 (2013).
63. Bauer, M.J., Cox, A.J. & Evers, D.J. Fast gapped read mapping for Illumina reads. *In ISMB, ISBC* (2010).
64. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
65. Rausch, T. *et al.* DELLY: structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* **28**, i333–i339 (2012).
66. Xi, R. *et al.* Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. *Proc. Natl. Acad. Sci. USA* **108**, E1128–E1136 (2011).
67. Kim, D. *et al.* TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol.* **14**, R36 (2013).
68. McPherson, A. *et al.* deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. *PLOS Comput. Biol.* **7**, e1001138 (2011).
69. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
70. Cibulskis, K. *et al.* Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat. Biotechnol.* **31**, 213–219 (2013).
71. Forster, M. *et al.* From next-generation sequencing alignments to accurate comparison and validation of single-nucleotide variants: the pibase software. *Nucleic Acids Res.* **41**, e16 (2013).
72. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
73. Koboldt, D.C. *et al.* VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res.* **22**, 568–576 (2012).
74. Albers, C.A. *et al.* Dindel: accurate indel calls from short-read data. *Genome Res.* **21**, 961–973 (2011).
75. Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat. Methods* **5**, 621–628 (2008).
76. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).
77. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**, 15545–15550 (2005).
78. Frisch, M., Klocke, B., Haltmeier, M. & Frech, K. LitInspector: literature and signal transduction pathway mining in PubMed abstracts. *Nucleic Acids Res.* **37**, W135–W140 (2009).
79. Ho Sui, S.J. *et al.* oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. *Nucleic Acids Res.* **33**, 3154–3164 (2005).
80. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164 (2010).
81. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061–1073 (2010).
82. Stade, B., Seelow, D., Thomsen, I., Krawczak, M. & Franke, A. GrabBLUR—a framework to facilitate the secure exchange of whole-exome and -genome SNV data using VCF files. *BMC Genomics* **15** (suppl. 4), S8 (2014).
83. Robinson, J.T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
84. Ratei, R. *et al.* Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial. *Klin. Padiatr.* **225** (suppl. 1), S34–S39 (2013).
85. Festing, M.F. & Altman, D.G. Guidelines for the design and statistical analysis of experiments using laboratory animals. *ILAR J.* **43**, 244–258 (2002).